Portfolio of the Week

[Websman]

I am finished running my picks through the VTP...

The stock that will give me a win this week is................................









is..............................
















is..............................












CFK!!!

That's right folks... I'm taking CFK long in the morning. CFK is oversold and began it's move back up today. The VTP will prevail.

[Lyehopper]

WOW! I'm in Awe!

I am finished running my picks through the VTP...

The stock that will give me a win this week

is................................

CFK!!!

That's right folks... I'm taking CFK long in the morning. CFK is oversold and began it's move back up today. The VTP will prevail.

ooooooooo..... A good one Websman!

CFK rates a "942.88" on the VTP scale, HUUUUGE!!!!.... A sure winner!

[IIC]

CFK...An interesting call...It very well may be headed back up...But I'd wait to see it get past 15...Betcha 20 bux you don't win...IIC

[Rob]

For The Record ...

For the record, I agree that the method Scifos outlined is more "true-to-life." On the other hand, this "competition," if you want to call it that, is pretty simple and has other things that don't happen in real life either. There's not a broker on the planet who will limit you to two trades a week. And what about brokers' fees? Shouldn't the people who trade positions mid-week have a little bit deducted from their score relative to those who hold the same stock all week? In real life it costs money to sell out of one position and buy another. Etc., etc. For those reasons I also understand the way Lye approaches it, i.e. keep it simple.

The "simplified" net gain method happened to work in my favor and against New-born Baby this week. Next week it may work the other way around, and in the end it all basically washes. The bottom line is it's all about finding profitable stocks to trade and having a little fun while we're at it. As a relative newbie here, I'm just trying to go with the flow.

[spikefader]

CFK: May the force be with you Vulcan! Star Wars meets Star Trek! hehe

Now I know the VTP isn't pattern based or channel based...... lol

[spikefader]

...just trying to go with the flow.

Dude, I applaud this. You're huge. May we all just try to go with the flow!

[Rob]

I appreciate that, Spike. Thanks. I'm getting off to a slow start in the contest with a couple of good stocks picked on the wrong weeks. I tell ya, it ain't easy picking stocks on a weekly basis, and especially for someone who tends to focus more on fundamentals.

[spikefader]

I appreciate that, Spike. Thanks. I'm getting off to a slow start in the contest with a couple of good stocks picked on the wrong weeks. I tell ya, it ain't easy picking stocks on a weekly basis, and especially for someone who tends to focus more on fundamentals.

Yep, ya got that right; it ain't easy! hehe This is tuff competition fer sure. But Kudos to ya fer cuttin' 'em loose early and calmly lookin' fer recovery. That'll hold you in good stead I reckon. IMCL was bilgey after that fine pop; it didn't even hit the price resistance! What's up with that! lol

[Websman]

CFK...An interesting call...It very well may be headed back up...But I'd wait to see it get past 15...Betcha 20 bux you don't win...IIC

Betcha 20 bux, I can burp louder than you...

[Lyehopper]

now THIS is a competition!!!!

Betcha 20 bux, I can burp louder than you...

I want in on the action.... I've got $20 on webs superior belching skills.

Who want's to place a side bet?

[New-born baby]

Belch-Aid

I want in on the action.... I've got $20 on webs superior belching skills.
Who want's to place a side bet?

Lye,
I don't bet, but if I did, I'd never bet against you on this one. I figure you'll give that Stinkin' Vulcan a blast of birdshot just as he's about to belch and win the contest.

[Lyehopper]

Lye,
I don't bet, but if I did, I'd never bet against you on this one. I figure you'll give that Stinkin' Vulcan a blast of birdshot just as he's about to belch and will the contest.

Actually I have a better and more effective method to assure Web's victory.... I have developed a carbonated GoJi brandy. Take one slug of this stuff and you can belch-sing the first AND second verse of Amazing Grace....

[Rob]

Imcl

IMCL was bilgey after that fine pop; it didn't even hit the price resistance! What's up with that!

That was not very uncharacteristic for this stock, and investors in this company have had to develop gastro-inteninal tracts made of cold-rolled steel in order to stay in. I've traded in and out of this company a few times over the past two years since Erbitux was first approved by the FDA for refractory colorectal cancer. I've even been short on it at times, getting back some of what I lost on it inititally. Imclone's biggest problem is a management and B.O.D. who are much better at science than they are at romancing Wall St. Generally speaking the street hates this company, but they can't ignore the fact that Erbitux is gaining market share and about to break into other indications, including Head & Neck cancer, for which the FDA granted "priority review" status and is due to render their decision any time on or before March 1. Some of the future indications which are currently in late-stage clinical trials include lung, pancreas, and earlier stage colorectal. There is compelling evidence that it will eventually come to used as a part of a "cocktail" mixture with DNA's Avastin, greatly extending the lives of colorectal cancer patients. It's a great drug with a somewhat lackluster management team. Their C.E.O. resigned in November, and they're currently fishing for a new one. The pop yesterday was due to a filing by Carl Ichan, disclosing that he's controlling a 9.8% stake and is changing his status from "passive" to "active," and that he's going to start leaning on the company to unlock the value for the shareholders. A possible takeover at $55 or more is a very real prospect at this point.

[Rob]

Medved Quote Tracker

To Spike, or Ski, or whomever may know ...

I've spent a little time trying to figure out how to get that backfill feature of the Medved software to work. I see that most of the services, including prophet, require a subscription or a registration. The only company I have an account with for now is Ameritrade. According to the help screens on Medved, if you set the backfill source to default, it will automatically use the company you've specified for streaming info., but I haven't been able to get it working. I select the backfill tool on a certain issue, and a little yellow box pops up telling me it's backfilling, but it never does. I let it run in the background about twenty minutes yesterday, and it still never did anything. Any idea what I'm missing? Thanks.

[Lyehopper]

Jiesen where are YOU!!!?

That was not very uncharacteristic for this stock, and investors in this company have had to develop gastro-inteninal tracts made of cold-rolled steel in order to stay in. I've traded in and out of this company a few times over the past two years since Erbitux was first approved by the FDA for refractory colorectal cancer. I've even been short on it at times, getting back some of what I lost on it inititally. Imclone's biggest problem is a management and B.O.D. who are much better at science than they are at romancing Wall St. Generally speaking the street hates this company, but they can't ignore the fact that Erbitux is gaining market share and about to break into other indications, including Head & Neck cancer, for which the FDA granted "priority review" status and is due to render their decision any time on or before March 1. Some of the future indications which are currently in late-stage clinical trials include lung, pancreas, and earlier stage colorectal. There is compelling evidence that it will eventually come to used as a part of a "cocktail" mixture with DNA's Avastin, greatly extending the lives of colorectal cancer patients. It's a great drug with a somewhat lackluster management team. Their C.E.O. resigned in November, and they're currently fishing for a new one. The pop yesterday was due to a filing by Carl Ichan, disclosing that he's controlling a 9.8% stake and is changing his status from "passive" to "active," and that he's going to start leaning on the company to unlock the value for the shareholders. A possible takeover at $55 or more is a very real prospect at this point.

Rob.... this sounds like a Jiesen conversation dude! He knows alot about these type companies.

Jiesen do you follow IMCL? or are you skeerd of being locked up alongside MS if you invest in it?lol